Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

BACKGROUND: In the CheckMate-141 trial, nivolumab conferred a survival benefit in patients with recurrent or metastatic refractory squamous cell carcinoma (SCC) head and neck cancer (HNC). Here, we examined the efficacy of nivolumab in patients with histological subtypes or primary sites of HNC not...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yasuyoshi, Fukuda, Naoki, Wang, Xiaofei, Urasaki, Tetsuya, Ohmoto, Akihiro, Nakano, Kenji, Yunokawa, Mayu, Ono, Makiko, Sato, Yukiko, Mitani, Hiroki, Tomomatsu, Junichi, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280058/
https://www.ncbi.nlm.nih.gov/pubmed/32581587
http://dx.doi.org/10.2147/CMAR.S249393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280058/
https://www.ncbi.nlm.nih.gov/pubmed/32581587
http://dx.doi.org/10.2147/CMAR.S249393

Ejemplares similares